After whole genome sequencing of samples from 38 patients with multiple myeloma (MM) had identified one patient with an activating mutation of *BRAF* (G469A), *BRAF* mutations have been intensively screened in MM patients.^[@bib1]^ Among 161 samples, 3 K601N and 4 V600E (the most common in melanoma) mutations were found in 4% of the patients.^[@bib1]^ This low incidence is still consistent with a recent study involving 32 MM samples that reported no *BRAF* mutation.^[@bib2]^ In the more specific field of extramedullary disease (EMD) in MM, Andrulis *et al.*^[@bib3]^ recently reported a significant association with *BRAF* exon 15 mutations. Notably, the V600E mutation was found in 8.5% of patients with EMD (4 out of 47) versus 1.5% of patients without EMD (3 out of 204). The EMD of the four patients harbouring *BRAF* V600E mutation (all soft tissue plasmacytomas) was primitive for one patient and secondary after one or several lines of treatments for the three others. This recent work contrasts with an older one in which no BRAF mutation was found in 65 fresh bone marrow samples from 18 patients with PCL and 47 patients with MM at diagnosis.^[@bib4]^ The incidence of EMD in MM is rare at diagnosis but extramedullary involvement increases with disease evolution. Spreading of MM cells out of the bone marrow is commonly associated with a poor outcome and resistance to salvage therapies.^[@bib5]^ In this context, the recent findings of Andrulis *et al.* raise the interest of identifying patients with EMD carrying the *BRAF* V600E mutation, who could benefit from the V600E-mutated BRAF protein targeted therapy, that is, vemurafenib.

The establishment of human myeloma cell lines (HMCLs) remains rare and has mainly been obtained in samples from patients who had massive and/or serous EMD (mostly secondary), whatever the origin of patient\'s samples, that is, bone marrow, peripheral blood, pleural effusion or ascites fluid.^[@bib6],\ [@bib7]^ Although these HMCLs mostly derived from end-stage disease, they retained the oncogenic abnormalities found at the time of diagnosis.^[@bib6],\ [@bib7]^ A recent study, which assessed the presence of *BRAF* mutation in six HMCLs, reported that U266 harboured the K601N mutation, suggesting that *BRAF* mutation could be frequent in HMCLs.^[@bib8]^ We thus screened 33 HMCLs for V600E *BRAF* mutation by sequencing exon 15 to determine whether vemurafenib could be a common therapeutic approach for patients with massive EMD, especially plasma cell leukaemia. In this collection, 2 HMCLs were derived from ascites fluid, 18 from peripheral blood, 12 from pleural effusion and 1 from subcutaneous sample ([Table 1](#tbl1){ref-type="table"}). Unfortunately, none of the HMCLs carried the V600E mutation ([Table 1](#tbl1){ref-type="table"}). U266 was retrieved in this screening to harbour the K601N *BRAF* mutation (66% of mutated allele) and no other *BRAF* mutation was found in the collection. U266 was subcloned in order to define whether the mutation was present in each cell. As shown in [Figure 1a](#fig1){ref-type="fig"}, all clones evaluated (*n*=17) harboured the mutation with the same proportion of 66%, as found within the parental cell line. Because U266 is known to carry a duplication of the q32q34 region of chromosome 7 where *BRAF* is located, it is likely that the mutated *BRAF* allele is duplicated.^[@bib9]^ We further determined the sensitivity of U266 and three *BRAF* wild-type cell lines to vemurafenib. All cell lines displayed a very weak sensitivity with IC~50~ values higher than 5 μ[M]{.smallcaps} ([Figure 1b](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). By contrast, in V600E-mutated melanoma cells, IC~50~ values were lower than 100 n[M]{.smallcaps}, whereas V600E unmutated cells (including cells carrying other *BRAF* mutations) required more than 1 μ[M]{.smallcaps} to display any sensitivity.^[@bib10]^ Although the *BRAF*-mutated HMCL did not carry any *RAS* mutation, 45% of HMCLs (15 out of 33) harboured a *K-* or *N-RAS* activating mutation ([Table 1](#tbl1){ref-type="table"}). Our findings show that *BRAF* mutation, in contrast to that of *RAS*,^[@bib1]^ is a rare event even in massive and/or serous EMD and that targeting *BRAF* V600E mutation with vemurafenib in MM could unfortunately be of limited value in patients with massive and/or serous EMD, such as pleural effusion or plasma cell leukaemia. Nevertheless, vemurafenib could be of high interest for patients with soft tissue plasmacytomas, in which the *BRAF* V600E mutation has been found, provided the mutation incidence should be significant in that infrequent MM presentation.
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![(**a**) *BRAF* exon 15 DNA sequencing was performed in U266 cell line and in 17 clones derived by limiting dilution assay. All sequenced clones harboured the same mutation proportion as illustrated in the figure. (**b**) Cells (30 000 cells per 0.2 ml) were seeded for 3 days in the presence of increasing concentrations of vemurafenib (Selleckchem, [www.selleckchem.com](http://www.selleckchem.com)). Proliferation was determined with the Alamar Blue Assay according to the manufacturer\'s instructions (AbD Serotec, Biorad, Marnes La Coquette, France). The data represent the mean±s.e.m. of three independent experiments performed in triplicate wells.](bcj201360f1){#fig1}

###### *BRAF* and *RAS* mutations in human myeloma cell lines

  *HMCLs*      *Disease at diagnosis*   *Sample*   *BRAF exon 15*   *K-RAS codons 12, 13 and 61*   *N-RAS codons 12, 13 and 61*   *Vemurafenib IC*~*50*~ *(μ[M]{.smallcaps})*
  ----------- ------------------------ ---------- ---------------- ------------------------------ ------------------------------ ---------------------------------------------
  AMO1                  PCT                AF            Wt                      Wt                             Wt                                      
  XG10                  PCT                AF            Wt                    G13G+R                           Wt                                      
  U266                   MM                PB         K601K+N                    Wt                             Wt                                    10
  ANBL6                  MM                PB            Wt                      Wt                             Wt                                      
  LP1                    MM                PB            Wt                      Wt                             Wt                                      
  NAN6                   MM                PB            Wt                      Wt                             Wt                                      
  NAN8                  PCL                PB            Wt                      Wt                             Wt                                      
  NAN9                   MM                PB            Wt                      Wt                             Wt                                      
  OPM2                   MM                PB            Wt                      Wt                             Wt                                    12
  SKMM2                 PCL                PB            Wt                      Wt                             Wt                                      
  XG5                    MM                PB            Wt                      Wt                             Wt                                      
  XG6                    MM                PB            Wt                      Wt                             Wt                                      
  XG11                  PCL                PB            Wt                      Wt                             Wt                                      
  RPMI8226               MM                PB            Wt                     G12A                            Wt                                      
  XG7                    MM                PB            Wt                     G12C                            Wt                                      
  KARPAS620             PCL                PB            Wt                     G12D                            Wt                                      
  NAN10                  MM                PB            Wt                      Wt                           G12G+R                                    
  XG1                    MM                PB            Wt                      Wt                            G12R                                     
  MDN                    MM                PB            Wt                      Wt                            G13D                                     
  NAN7                   MM                PB            Wt                      Wt                            Q61H                                     
  JIM3                   MM                PE            Wt                      Wt                             Wt                                      
  KMS11                  MM                PE            Wt                      Wt                             Wt                                      
  KMS12PE                MM                PE            Wt                      Wt                             Wt                                    18
  NAN1                   MM                PE            Wt                      Wt                             Wt                                      
  SBN                   PCT                PE            Wt                      Wt                             Wt                                      
  XG4                    MM                PE            Wt                      Wt                             Wt                                      
  XG2                    MM                PE            Wt                     G12A                            Wt                                      
  JJN3                   MM                PE            Wt                      Wt                            G12D                                     
  NCI-H929               MM                PE            Wt                      Wt                            G13D                                   9.5
  L363                  PCL                PE            Wt                      Wt                            Q61H                                     
  NAN3                   MM                PE            Wt                      Wt                            Q61K                                     
  XG3                   PCL                PE            Wt                      Wt                            Q61K                                     
  KMM1                   MM                SC            Wt                      Wt                            G13D                                     

Abbreviations: AF, ascites fluid; MM, multiple myeloma; PB, peripheral blood; PCL, plasma cell leukemia; PCT, plasmacytoma; PE, pleural effusion; SC, subcutaneous; Wt, wild type.

HMCLs were previously reported.^[@bib6],\ [@bib7]^ DNA *BRAF* sequencing was performed using primers located within introns 14 and 15 (forward: 5′-ACTCTTCATAATGCTTGCTCTGA-3′, reverse-5′-AGTAACTCAGCAGCATCTCAGG-3′, respectively). *K-* and *N-RAS* sequencing was previously reported.^[@bib6]^

For NAN8 and NAN10 cell lines, screening of *BRAF* mutation was also performed in the cryopreserved myeloma peripheral cells from which the cell lines were established, and the same results were found, that is, no *BRAF* mutation (data not shown). No BRAF mutation was found in four other PCLs (data not shown).

Vemurafenib IC~50~ values were defined as the doses that inhibited 50% of proliferation (see [Figure 1b](#fig1){ref-type="fig"}).
